DNA 'nanoswitch' could support quick, point-of-care Dx

Researchers at the University of California, Santa Barbara have developed technology that could eventually support quick, inexpensive diagnostics that mimic a process in nature to do their work. The tests, designed to work in minutes, use a nanometer-scale DNA "switch" to detect antibodies for a number of diseases.  The research team says their finding could help develop a new class of point-of-care diagnostic devices for everything from autoimmune diseases to allergies. Details are published in the Journal of the American Chemical Society. Research | Release

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.